Genetic LifeSpan publishes peer-reviewed review on biological age testing

Genetic LifeSpan says a new peer-reviewed review in the American Journal of Biomedical Science & Research supports broader clinical use of biological age measurement and its AgeCode Premier platform. The paper argues that biological age can offer a more actionable view of health risk, intervention response, and aging than chronological age alone.

Why it matters: - Biological age testing is moving from a niche concept toward a clinical tool for earlier risk detection, personalized interventions and tracking health outcomes. - Genetic LifeSpan is positioning AgeCode Premier as part of that shift for physicians, clinics and consumers. - The publication argues that chronological age alone misses important signals from genetics, inflammation, metabolism, immune function and organ-system health.

What happened: - Genetic LifeSpan announced the publication of a peer-reviewed scientific review, “From Biological Age to Clinical Phenotype: State of the Science in DNA Methylation, Multi-Omic Clocks, and Translational Utility,” in the American Journal of Biomedical Science & Research. - The review was co-authored by Jonathan R.T. Lakey, PhD, Laura Capina, PhD, Jeffery M. Gaal, Jaime Raijman, Elliott Greenspan, Ian Jenkins, Krista Casazza and Adam Vincent Gilmer. - The company said the paper supports clinical adoption of AgeCode Premier, its flagship biological intelligence platform.

The details: - The review covers biological age testing, DNA methylation analysis, polygenic risk scoring, multi-omic biomarkers and organ-system aging assessments. - The paper says biological age assessments provide a more comprehensive understanding of how genetics, lifestyle, environment and biology shape an individual’s aging trajectory. - The review says biological age tools can help monitor the effectiveness of exercise, nutrition programs, regenerative medicine, stem cell therapies, peptide protocols, hyperbaric oxygen therapy and red light therapy. - AgeCode Premier combines genomic analysis, DNA methylation measurements and multi-system biomarker profiling. - The platform is designed to show biological aging, pace of aging, organ-system health, inherited predispositions and wellness optimization opportunities. - For physicians and clinics, the platform is intended to establish baselines, personalize treatment strategies, monitor intervention effectiveness, improve patient engagement and support measurable outcomes. - For consumers, the platform is intended to help identify vulnerabilities and guide long-term self-care decisions. - Genetic LifeSpan said the company’s broader ecosystem includes genetics, epigenetics, cardiovascular intelligence, biological age assessment, preventative health technologies and data-driven wellness strategies. - The company also said its products are aimed at healthier aging, improved performance and informed decision-making. - Genetic LifeSpan said the article reinforces a growing scientific consensus that biological age may be more actionable than chronological age alone.

Between the lines: - The publication is as much a market signal as a scientific one. Genetic LifeSpan is using the review to legitimize a product category and expand the case for routine biological age testing. - The company’s messaging reflects a broader shift in longevity medicine toward measurable interventions and outcome tracking. - Dr. Jonathan R.T. Lakey said the integration of genomic, epigenetic and biomarker data could help move care toward earlier intervention and better prevention.

What's next: - Genetic LifeSpan said biological age testing could become a foundational component of modern healthcare, longevity medicine, concierge medicine, functional medicine, integrative medicine, regenerative medicine and preventive wellness programs. - The company said it will continue advancing clinically relevant biological intelligence tools for healthcare professionals and consumers. - The company’s website is available as More information.